Prior to ElevateBio, Kareem was Head of Business Development and Corporate Strategy at Evelo Biosciences. He played an integral role in the company’s $85 million initial public offerings (IPO) and private Series B and C fundraising rounds, helping to raise over $200 million. While at Celgene, he executed over a dozen deals with a total value greater than $5 billion and actively partnered with the science team to develop a cancer immunotherapy strategy which ultimately guided Celgene into the rapidly developing field of immuno-oncology (IO). He also led the B-cell maturation antigen (BCMA) collaboration with bluebird bio and the $1 billion, 10-year collaboration with Juno Therapeutics, focused on Chimeric Antigen Receptor Technology (CAR-T) and T-cell Receptor (TCR) technologies. Kareem started his career at Vertex Pharmaceuticals in formulation development.